New hope for tough blood cancers: experimental drug rebecsinib enters early trial
NCT ID NCT07250646
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 23 times
Summary
This early-phase study tests a new drug called rebecsinib in 28 people with two types of blood cancer: secondary acute myeloid leukemia (sAML) that has come back or not responded to treatment, or higher-risk myelofibrosis (MF). The goal is to find the safest and most effective dose by giving the drug as an infusion four times per 28-day cycle for up to six cycles. Researchers will monitor side effects and check if the cancer shrinks or disappears.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UC San Diego Moores Cancer Center
San Diego, California, 92093, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.